Amyloid beta peptide, 4-hydroxynonenal and apoptosis

Current Alzheimer Research

Volumn 3, Issue 4, 2006, Pages 359-364

  Lovell, Mark A ^a,b,c   Markesbery, William R ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ACROLEIN; AMYLOID BETA PROTEIN; CASPASE INHIBITOR; HYDROGEN PEROXIDE; IRON; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR;

ALZHEIMER DISEASE; APOPTOSIS; CELL CULTURE; CELL DEATH; DEGENERATIVE DISEASE; HUMAN; IN VITRO STUDY; LIPID PEROXIDATION; NEUROTOXICITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ALDEHYDES; AMYLOID BETA-PROTEIN; ANIMALS; APOPTOSIS; BRAIN; CELLS, CULTURED; HUMANS; LIPID PEROXIDATION; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATIVE STRESS;

EID: 33748457094     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506778249506     Document Type: Review

References (114)

1. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med;10 Suppl: S18-25 (2004).
2. Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 71(5): 2034-40 (1998).
3. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65(5): 2146-56 (1995).
4. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64(7): 1152-6 (2005).
5. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36(5): 747-51 (1994).
6. Mecocci P, Polidori MC, Ingegni T, Cherubini A, Chionne F, Cecchetti R, et al. Oxidative damage to DNA in lymphocytes from AD patients. Neurology 51(4): 1014-7 (1998).
7. Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G, et al. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 26(5): 567-73 (2005).
8. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 93(4): 953-62 (2005).
9. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23(1): 81-8 (1998).
10. Svennerholm L, Gottfries CG. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem 62(3): 1039-47 (1994).
11. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45(8): 1594-601 (1995).
12. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18(5): 457-61 (1997).
13. Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22(2): 187-94 (2001).
14. Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ. 4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 56(8): 866-71 (1997).
15. Montine KS, Reich E, Neely MD, Sidell KR, Olson SJ, Markesbery WR, et al. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J Neuropathol Exp Neurol 57(5): 415-25 (1998).
16. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology 52(3): 562-5 (1999).
17. Nourooz-Zadeh J, Liu EH, Yhlen B, Anggard EE, Halliwell B. F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem 72(2): 734-40 (1999).
18. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19(1): 33-6 (1998).
19. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 149(1): 21-8 (1996).
20. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, et al. Oxidative damage in Alzheimer's. Nature 382(6587): 120-1 (1996).
21. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 91(12): 5710-4 (1994).
22. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A 91(16): 7787-91 (1994).
23. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 15(3): 93-101 (2000).
24. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56(3): 303-8 (1999).
25. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256(3): 240-6 (2004).
26. Wang J, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem In Press (2005).
27. Ding Q, Markesbery WR, Chen Q, Li F, Keller JN. Ribosome dysfunction is an early event in Alzheimer's disease. J Neurosci 25(40): 9171-5 (2005).
28. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 59(6): 972-6 (2002).
29. Islam-Williams T, Lovell MA, Lynn BC. Analysis of derivatized biogenic aldehydes by HPLC tandem mass spectrometry. Anal Chem 77: 3383-3389 (2005).
30. Pappolla MA, Omar RA, Kim KS, Robakis NK. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am J Pathol 140(3): 621-8 (1992).
31. Zemlan FP, Thienhaus OJ, Bosmann HB. Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation. Brain Res 476(1): 160-2 (1989).
32. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81(2): 741-66 (2001).
33. Behl C. Vitamin E protects neurons against oxidative cell death in vitro more effectively than 17-beta estradiol and induces the activity of the transcription factor NF-kappaB. J Neural Transm 107(4): 393-407 (2000).
34. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A 73(7): 2424-8 (1976).
35. Guo Q, Christakos S, Robinson N, Mattson MP. Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function. Proc Natl Acad Sci U S A 95(6): 3227-32 (1998).
36. Harris ME, Hensley K, Butterfield DA, Leedle RA, Carney JM. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp Neurol 131(2): 193-202 (1995).
37. Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, et al. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152(4): 871-7 (1998).
38. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70(5): 2212-5 (1998).
39. Weeks BS, Papadopoulos V, Dym M, Kleinman HK. cAMP promotes branching of laminin-induced neuronal processes. J Cell Physiol 147(1): 62-7 (1991).
40. Kruman I, Bruce-Keller AJ, Bredesen D, Waeg G, Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci 17(13): 5089-100 (1997).
41. Mattson MP, Pedersen WA. Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Int J Dev Neurosci 16(7-8): 737-53 (1998).
42. Pedersen WA, Cashman NR, Mattson MP. The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells. Exp Neurol 155(1): 1-10 (1999).
43. Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol 44(5): 819-24 (1998).
44. Subramaniam R, Roediger F, Jordan B, Mattson MP, Keller JN, Waeg G, et al. The lipid peroxidation product, 4-hydroxy-2-transnonenal, alters the conformation of cortical synaptosomal membrane proteins. J Neurochem 69(3): 1161-9 (1997).
45. Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K, Shelanski ML. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci 20(4): 1386-92 (2000).
46. Becker EB, Bonni A. Cell cycle regulation of neuronal apoptosis in development and disease. Prog Neurobiol 72(1): 1-25 (2004).
47. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2(11): 806-19 (2001).
48. Julien JP. Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell 104(4): 581-91 (2001).
49. Compton MM. A biochemical hallmark of apoptosis: internucleosomal degradation of the genome. Cancer Metastasis Rev 11(2): 105-19 (1992).
50. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94(4): 491-501 (1998).
51. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90(3): 405-13 (1997).
52. Polster BM, Fiskum G. Mitochondrial mechanisms of neural cell apoptosis. J Neurochem 90(6): 1281-9 (2004).
53. Miller FD, Pozniak CD, Walsh GS. Neuronal life and death: an essential role for the p53 family. Cell Death Differ 7(10): 880-8 (2000).
54. Sax JK, El-Deiry WS. p53 downstream targets and chemosensitivity. Cell Death Differ 10(4): 413-7 (2003).
55. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370(6486): 220-3 (1994).
56. Chipuk JE, Maurer U, Green DR, Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4(5): 371-81 (2003).
57. Culmsee C, Mattson MP. p53 in neuronal apoptosis. Biochem Biophys Res Commun 331(3): 761-77 (2005).
58. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 77(1): 220-8 (2001).
59. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death - inducing signaling complex. Cell 85(6): 817-27 (1996).
60. Chang LK, Putcha GV, Deshmukh M, Johnson EM, Jr. Mitochondrial involvement in the point of no return in neuronal apoptosis. Biochimie 84(2-3): 223-31 (2002).
61. Zhang X, Chen J, Graham SH, Du L, Kochanek PM, Draviam R, et al. Intranuclear localization of apoptosis-inducing factor (AIF) and large scale DNA fragmentation after traumatic brain injury in rats and in neuronal cultures exposed to peroxynitrite. J Neurochem 82(1): 181-91 (2002).
62. Cao G, Clark RS, Pei W, Yin W, Zhang F, Sun FY, et al. Translocation of apoptosis-inducing factor in vulnerable neurons after transient cerebral ischemia and in neuronal cultures after oxygen-glucose deprivation. J Cereb Blood Flow Metab 23(10): 1137-50 (2003).
63. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297(5579): 259-63 (2002).
64. Marzo I, Brenner C, Zamzami N, Susin SA, Beutner G, Brdiczka D, et al. The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. J Exp Med 187(8): 1261-71 (1998).
65. Pastorino JG, Chen ST, Tafani M, Snyder JW, Farber JL. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 273(13): 7770-5 (1998).
66. Eskes R, Antonsson B, Osen-Sand A, Montessuit S, Richter C, Sadoul R, et al. Bax-induced cytochrome C release from mitochondria is independent of the permeability transition pore but highly dependent on Mg2+ ions. J Cell Biol 143(1): 217-24 (1998).
67. Polster BM, Basanez G, Young M, Suzuki M, Fiskum G. Inhibition of Bax-induced cytochrome c release from neural cell and brain mitochondria by dibucaine and propranolol. J Neurosci 23(7): 2735-43 (2003).
68. Wigdal SS, Kirkland RA, Franklin JL, Haak-Frendscho M. Cytochrome c release precedes mitochondrial membrane potential loss in cerebellar granule neuron apoptosis: lack of mitochondrial swelling. J Neurochem 82(5): 1029-38 (2002).
69. Brustovetsky N, Dubinsky JM, Antonsson B, Jemmerson R. Two pathways for tBID-induced cytochrome c release from rat brain mitochondria: BAK- versus BAX-dependence. J Neurochem 84(1): 196-207 (2003).
70. De Giorgi F, Lartigue L, Bauer MK, Schubert A, Grimm S, Hanson GT, et al. The permeability transition pore signals apoptosis by directing Bax translocation and multimerization. FASEB J 16(6): 607-9 (2002).
71. Lovell MA, Xiong S, Markesbery WR, Lynn BC. Quantitative proteomic analysis of mitochondria from primary neuron cultures treated with amyloid beta peptide. Neurochem Res 30(1): 113-22 (2005).
72. Perry G, Nunomura A, Lucassen P, Lassmann H, Smith MA. Apoptosis and Alzheimer's disease. Science 282(5392): 1268-9 (1998).
73. Perry G, Nunomura A, Smith MA. A suicide note from Alzheimer disease neurons? Nat Med 4(8): 897-8 (1998).
74. Dragunow M, Faull RL, Lawlor P, Beilharz EJ, Singleton K, Walker EB, et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 6(7): 1053-7 (1995).
75. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97(3): 395-406 (1999).
76. Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ . Acta Neuropathol (Berl) 89(1): 35-41 (1995).
77. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 9(17): 2143-56 (1995).
78. Guo Q, Fu W, Xie J, Luo H, Sells SF, Geddes JW, et al. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat Med 4(8): 957-62 (1998).
79. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373(6514): 523-7 (1995).
80. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4(1): 97-100 (1998).
81. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 16(18): 5795-811 (1996).
82. Yamatsuji T, Matsui T, Okamoto T, Komatsuzaki K, Takeda S, Fukumoto H, et al. G protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP. Science 272(5266): 1349-52 (1996).
83. Yamatsuji T, Okamoto T, Takeda S, Murayama Y, Tanaka N, Nishimoto I. Expression of V642 APP mutant causes cellular apoptosis as Alzheimer trait-linked phenotype. EMBO J 15(3): 498-509 (1996).
84. Eckert A, Marques CA, Keil U, Schussel K, Muller WE. Increased apoptotic cell death in sporadic and genetic Alzheimer's disease. Ann N Y Acad Sci 1010: 604-9 (2003).
85. Lovell MA, Xie C, Xiong S, Markesbery WR. Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. Brain Res 983(1-2): 84-96 (2003).
86. Haber DA, Englert C, Maheswaran S. Functional properties of WT1. Med Pediatr Oncol 27(5): 453-5 (1996).
87. Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher FJ, 3rd, Kim SJ. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol 8(5): 595-602 (1994).
88. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ, 3rd. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 257(5070): 674-8 (1992).
89. Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG, et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 14(19): 4662-75 (1995).
90. Gashler AL, Bonthron DT, Madden SL, Rauscher FJ, 3rd, Collins T, Sukhatme VP. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci U S A 89(22): 10984-8 (1992).
91. Harrington MA, Konicek B, Song A, Xia XL, Fredericks WJ, Rauscher FJ, 3rd. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 268(28): 21271-5 (1993).
92. Madden SL, Cook DM, Morris JF, Gashler A, Sukhatme VP, Rauscher FJ, III. Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science 253(5027): 1550-3 (1991).
93. Wang ZY, Madden SL, Deuel TF, Rauscher FJ, 3rd. The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem 267(31): 21999-2002 (1992).
94. Werner H, Re GG, Drummond IA, Sukhatme VP, Rauscher FJ, 3rd, Sens DA, et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci U S A 90(12): 5828-32 (1993).
95. Werner H, Shen-Orr Z, Rauscher FJ, 3rd, Morris JF, Roberts CT, Jr., LeRoith D. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 15(7): 3516-22 (1995).
96. Murata Y, Kudoh T, Sugiyama H, Toyoshima K, Akiyama T. The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells. FEBS Lett 409(1): 41-5 (1997).
97. Camandola S, Poli G, Mattson MP. The lipid peroxidation product 4-hydroxy-2,3-nonenal increases AP-1-binding activity through caspase activation in neurons. J Neurochem 74(1): 159-68 (2000).
98. Lo YY, Wong JM, Cruz TF. Reactive oxygen species mediate cytokine activation of c-Jun NH2-terminal kinases. J Biol Chem 271(26): 15703-7 (1996).
99. Parola M, Robino G, Marra F, Pinzani M, Bellomo G, Leonarduzzi G, et al. HNE interacts directly with JNK isoforms in human hepatic stellate cells. J Clin Invest 102(11): 1942-50 (1998).
100. Kummer JL, Rao PK, Heidenreich KA. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem 272(33): 20490-4 (1997).
101. Le-Niculescu H, Bonfoco E, Kasuya Y, Claret FX, Green DR, Karin M. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol Cell Biol 19(1): 751-63 (1999).
102. Watson A, Eilers A, Lallemand D, Kyriakis J, Rubin LL, Ham J. Phosphorylation of c-Jun is necessary for apoptosis induced by survival signal withdrawal in cerebellar granule neurons. J Neurosci 18(2): 751-62 (1998).
103. McDonald DR, Bamberger ME, Combs CK, Landreth GE. beta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J Neurosci 18(12): 4451-60 (1998).
104. Pyo H, Jou I, Jung S, Hong S, Joe EH. Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport 9(5): 871-4 (1998).
105. Rosenblum WI. The presence, origin, and significance of A beta peptide in the cell bodies of neurons. J Neuropathol Exp Neurol 58(6): 575-81 (1999).
106. Ji C, Amarnath V, Pietenpol JA, Marnett LJ. 4-hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c release. Chem Res Toxicol 14(8): 1090-6 (2001).
107. Liu W, Kato M, Akhand AA, Hayakawa A, Suzuki H, Miyata T, et al. 4-hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. J Cell Sci 113 (Pt 4): 635-41 (2000).
108. Zhang W, He Q, Chan LL, Zhou F, El Naghy M, Thompson EB, et al. Involvement of caspases in 4-hydroxy-alkenal-induced apoptosis in human leukemic cells. Free Radic Biol Med 30(6): 699-706 (2001).
109. Tamagno E, Robino G, Obbili A, Bardini P, Aragno M, Parola M, et al. H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol 180(2): 144-55 (2003).
110. Rabacchi SA, Friedman WJ, Shelanski ML, Troy CM. Divergence of the apoptotic pathways induced by 4-hydroxynonenal and amyloid beta-protein. Neurobiol Aging 25(8): 1057-66 (2004).
111. Estus S, Zaks WJ, Freeman RS, Gruda M, Bravo R, Johnson EM, Jr. Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J Cell Biol 127(6 Pt 1): 1717-27 (1994).
112. Ham J, Babij C, Whitfield J, Pfarr CM, Lallemand D, Yaniv M, et al. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 14(5): 927-39 (1995).
113. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 341 (Pt 2): 233-49 (1999).
114. Yoo BC, Fountoulakis M, Cairns N, Lubec G. Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis 22(1): 172-9 (2001).